AbbVie Inc.
Develops and sells pharmaceutical medicines, therapies, and cosmetic injectables, spanning oncology, immunology, eye care, neurology, and aesthetics globally.
As of Sep 1, 2026
Summary
AbbVie is a healthcare company trading on the NYSE at $256.42 with a market capitalisation of $451 billion. The stock shows a neutral technical bias currently, though it has delivered a 27.2 percent return over the past year and gained 2.2 percent in the last month. Today it moved up 0.4 percent.
Price history
As of Aug 31, 2026
Performance
+1.39%
-3.06%
+2.18%
+21.28%
+14.88%
+27.15%
As of Aug 31, 2026
Technical indicators
- 51.7
- -0.41Bearish
- 50: 252.01 · 200: 225.16Bullish
- $252.25 / $259.79
Technical Bias
AbbVie Inc.'s technical indicators are split: the moving averages suggest upward momentum with the stock trading above both its 50-day (252.01) and 200-day (225.16) averages, whilst MACD shows bearish divergence at -0.41 and RSI sits neutral at 51.7. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Aug 31, 2026
Fundamentals
- $451B
- 72.99
- $3.50
- 9.80%
- +10.2%
- $17.8B
- 0.28
- $189.40 – $267.47
- 2.71%
- Jul 15, 2026
- —
As of Sep 1, 2026
Latest news
As of Sep 1, 2026
MonkeyTrade's Take on AbbVie Inc.
Short-term outlook
The short-term setup leans mildly bearish: MACD is showing negative momentum even as RSI sits neutral at 51.7, suggesting the recent +2.2% one-month gain is losing steam. The longer-term trend still favours the bulls, with price above both the 50-day ($252.01) and 200-day ($225.16) averages. A break below the $252.25 support would confirm the softer near-term tone, while a push through $259.79 resistance would put the bullish trend back in charge.
Medium-term outlook
AbbVie's 10.2% revenue growth and 2.7% dividend yield point to a business still expanding steadily, but a 72.99 P/E against a comparatively slim 9.8% profit margin suggests the market has priced in a lot more than current earnings justify, leaving little room for disappointment. With the technical picture reading neutral, the medium-term case hinges on margins widening to catch up with that valuation; a step-up in profitability would be the development to watch.
Key risks
- A price-to-earnings ratio of 72.99 sits well above typical market levels, meaning a lot of future growth is already priced in, which raises the risk of a sharp pullback if results disappoint.
- AbbVie's profit margin of 9.8% is relatively thin for a large pharmaceutical company, leaving less room to absorb cost pressures or pricing setbacks.
- The stock trades near the top of its 52-week range at $256.42, close to the $267.47 high, so it has limited room for error if sentiment shifts.
- Competitive pressure is evident in crowded therapeutic areas like palmoplantar pustulosis, where AbbVie is named alongside Johnson & Johnson, Novartis, Amgen, UCB and others, underlining the risk of market share erosion in key treatment
About AbbVie Inc.
AbbVie Inc. (NYSE: ABBV) is a major player in the Healthcare sector, operating within the Drug Manufacturers - General industry. With a market capitalisation of $451B, it stands as one of the larger pharmaceutical companies that retail investors keep on their radar, reflecting its broad footprint and established presence in the drugs sector.
Looking at AbbVie's key figures, the price-to-earnings ratio of 72.99 suggests the market is pricing the stock well above typical earnings multiples, which can point to elevated growth expectations or a temporary dip in reported earnings. Meanwhile, the dividend yield of +2.7% shows the company returns a portion of its earnings to shareholders regularly, a detail income-focused investors often factor into their research when assessing a stock like ABBV alongside its sector peers.
How to trade AbbVie Inc.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.